GATA2 plays a key role in driving prostate cancer aggressiveness: GATA2 acts as a pioneer transcription factor that increases AR binding and activity and regulates a core subset of clinically relevant genes in an AR-independent manner, thus suggesting that GATA2 is a potential target in prostate cancer therapy [652]. The gene discussed is AR; the disease is prostate carcinoma.